Kyowa Kirin Co., Ltd. · TSE:4151
Kyowa Kirin — ESG Presentation (October 2025)
42 slides from Kyowa Kirin's sustainability presentation, Oct 9, 2025
Slide 1: Kyowa Kirin Sustainability Meeting
Kyowa Kirin Sustainability Meeting Kyowa Kirin’s initiatives for realizing a sustainable society and its business October 9, 2025
Slide 2: Forward-looking statements disclaimer
This document contains certain forward‐looking statements relating to such items as the company’s (including its domestic and overseas subsidiaries) forecasts, targets and plans. These forward‐looking statements are based upon information available to the company at the present time and upon reasona
Slide 3: Agenda
Agenda 1. Overview Kyowa Kirin's Sustainability Chairman and Chief Executive Officer (CEO) Masashi Miyamoto, Ph.D. Story for Vision 2030 and KABEGOE Principles, aiming to realize our Vision 2030 2. Feature Stable supply and acceleration of development Managing Executive Officer, Manufacturing
Slide 4: © Kyowa Kirin Co., Ltd.
@yowa KIRIN 4 © Kyowa Kirin Co., Ltd.
Slide 5: Kyowa Kirin's Sustainability
Kyowa Kirin's Sustainabillity The sustainability of the Kyowa Kirin Group means to co-create life-changing value with social stakeholders to make people (facing illness) smile. We will achieve both social sustainability and our own sustainability through realizing our vision. The promotion of sustai
Slide 6: Our Philosophy and Core Value
Our Philosophy and Core Value Transform lives with passion and excitement. Challenge the status quo in all of our work. Our Philosophy The Kyowa Kirin Group companies strive to contribute to the health and wellbeing of people around the world Core Values by creating new value through the pursuit of
Slide 7: Vision 2030
Vision 2030 Provide Kyowa Kirin will realize the successful creation pharmaceuticals for and delivery of life-changing value* that unmet medical needs ultimately makes people smile, as a Japan- We are focused on developing medicines for diseases where there is a clear patient based Global Specialty
Slide 8: Strategies for creating and delivering life-changing value - Story for Vision 2030
Strategies for creating and delivering life-changing value - Story for Vision 2030 In the midst of major environmental changes, we formulated the Story for Vision 2030 to further ensure the realization of our vision. While increasing the resolution of the vision, we will link strategies and issues m
Slide 9: KABEGOE Principles
KABEGOE Principles Be Brave and Agile Be Curious and Keep Learning Innovation Make a Difference Patient Centric Ownership Talent Developer Commitment to Life Super Team with Shared Vision Do the Right Thing Inspire Others Care for Others Create Spaces for All the Voices Integrity Teamwork/Wa 9 © Kyo
Slide 10: Story for Vision 2030 and KABEGOE Principles to Realize Vision 2030
Vision 2030 Story for Vision 2030 and Kyowa Kirin will realize the successful creation and delivery of life-changing value that ultimately makes people KABEGOE Principles to smile, as a Japan-based Global Specialty Pharmaceutical company built on the diverse team of experts with shared Realize Visio
Slide 11: Value Creation Story
Value Creation Story The Story for Vision 2030, formulated as a strategy to create and deliver life-changing value, is closely linked to the business model outlined in this value creation story—and to intellectual capital—a key source of our competitiveness. Kyowa Kirin strives to create social and
Slide 12: Materiality
Materiality Kyowa Kirin has determined its materiality (key management issues) for achieving Vision 2030. In 2023, we clarified the relationship between our vision, strategy, and materiality, and since then, we have been revising our materiality in line with environmental changes when formulating ou
Slide 13: Materiality
Materiality 2024’s topics 2025’s topic Kyowa Kirin has determined its materiality (key management issues) for achieving Vision 2030. In 2023, we clarified the relationship between our vision, strategy, and materiality, and since then, we have been revising our materiality in line with environmental
Slide 14: Feature
Feature 14 © Kyowa Kirin Co., Ltd.
Slide 15: Patient Centric
Patient Centric Everyone involved in the development and manufacturing of pharmaceuticals will continue to place patients at the center, delivering life-changing value more quickly and reliably. Patient centricity activities by the Manufacturing Division have been implemented since 2022. Commitment
Slide 16: Manufacturing Strategy for Accelerating Development
Manufacturing Strategy for Accelerating Development 16 © Kyowa Kirin Co., Ltd.
Slide 17: Strategies for creating and delivering life-changing value - Story for Vision 2030
Strategies for creating and delivering life-changing value - Story for Vision 2030 In the midst of major environmental changes, we formulated the Story for Vision 2030 to further ensure the realization of our vision. While increasing the resolution of the vision, we will link strategies and issues m
Slide 18: Manufacturing Strategy Aligned with Story for Vision 2030
Manufacturing Strategy for Accelerating Development Manufacturing Strategy Aligned with Story for Vision 2030 A system to accelerate pipeline development is being established through strategic allocation of manufacturing resources to the biopharmaceutical and GCT fields. Small molecules: Downsizin
Slide 19: Acceleration of early-stage development
Manufacturing Strategy for Accelerating Development Acceleration of early-stage development By fully leveraging extensive experience in antibody development, development is being accelerated from the perspective of manufacturing technology. Aiming to start clinical trials at an early stage and deliv
Slide 20: Acceleration of late-stage development toward the launch phase
Manufacturing Strategy for Accelerating Development Acceleration of late-stage development toward the launch phase The concept is to standardize the equipment specifications of Takasaki Plant HB7 Building and the plant in Sanford. The start-up of the plant in Sanford enables smooth scale-up and tech
Slide 21: Progress of plant construction in Sanford, North Carolina
Manufacturing Strategy for Accelerating Development Progress of plant construction in Sanford, North Carolina Construction is proceeding as planned with strict management of schedule and budget. (Sept. 2025) 21 © Kyowa Kirin Co., Ltd.
Slide 22: Plant in Sanford: Toward a reliable start of operations
Manufacturing Strategy for Accelerating Development Plant in Sanford: Toward a reliable start of operations. Under focused efforts on equipment and system design, and talent acquisition—steady progress is being made toward operation in 2027 Global cross- functional collaboration system Penetration o
Slide 23: Building a Robust Foundation for Stable Supply
Building a Robust Foundation for Stable Supply 23 © Kyowa Kirin Co., Ltd.
Slide 24: Challenges and Measures in Stable Supply Management
Building a Robust Foundation for Stable Supply Challenges and Measures in Stable Supply Management To enable more reliable supply of high-quality products, collaboration between manufacturing and quality is being implemented to address these challenges. Strengthening in-house manufacturing system
Slide 25: Need to Strengthen Biopharmaceutical Human Resource Development
Building a Robust Foundation for Stable Supply Need to Strengthen Biopharmaceutical Human Resource Development External Environmental Changes Shortage of biopharmaceutical talent Stable supply of Increased talent mobility pharmaceuticals Human resource development Internal Environmental Changes syst
Slide 26: Biopharmaceutical Talent Development
Building a Robust Foundation for Stable Supply Biopharmaceutical Talent Development The operation of the training rooms equipped in the HB7 Building enables systematic acquisition of practical skills (Manufacturing and Quality Control). Acquisition of manufacturing and analytical knowledge Pract
Slide 27: Biopharmaceutical Talent Development
Building a Robust Foundation for Stable Supply Biopharmaceutical Talent Development Wave cell bioreactor Single use bioreactor Mixer Drug Substance: Drug Substance: Drug Substance and Pre-cultivation process Production cultivation Drug Product: process Solution preparation process, intermediate stir
Slide 28: Strengthening Human Resource and Manufacturing Capabilities at Kyowa Kirin
Building a Robust Foundation for Stable Supply Strengthening Human Resource and Manufacturing Capabilities at Kyowa Kirin Takasaki HB7 Building Completed in 2025 Acceleration of early-stage development United Scheduled for Expansion of manufacturing capacity States Plant in Sanford completion in
Slide 29: Aiming for Further Contributions to Patients
Aiming for Further Contributions to Patients 29 © Kyowa Kirin Co., Ltd.
Slide 30: Patient Centric
Aiming for Further Contributions to Patients Patient Centric Everyone involved in the development and manufacturing of pharmaceuticals will continue to place patients at the center, delivering life-changing value more quickly and reliably. Patient centricity activities by the Manufacturing Division
Slide 31: Co-creation of Value with Stakeholders
Appendix Co-creation of Value with Stakeholders 31 © Kyowa Kirin Co., Ltd.
Slide 32: Stakeholders
Stakeholders Creating value relies heavily on cooperation and collaboration with various stakeholders. Here we illustrate the connections between stakeholders who play a central role in value creation and the value chain as defined by our business model and value creation story. In particular, we be
Slide 33: Initiatives for a Sustainable Society
Initiatives for a Sustainable Society Establishment of the Kyowa Kirin Group Business Partner Management Policy Joining PSCI Clarification of the Policy for Business Partners in PSCI membership in 2024 Kyowa Kirin Group Collaboration with Global Pharmaceutical Actions Kyowa Kirin Group encourage
Slide 34: Initiatives for a Sustainable Society
Initiatives for a Sustainable Society Revised Kyowa Kirin Group Environmental Policy Addressing Climate Change Clarifying the Positioning of Environmental Initiatives Scope1+2: Promote renewable energy switching within the Kyowa Kirin Group smoothly Key Environmental Initiatives for Kyowa Kirin CO
Slide 35: Environmental Preservation Highlights: From the 2024 Integrated Report
Environmental Preservation Highlights: From the 2024 Integrated Report Addressing climate change Biodiversity Satoyama Biotope Futamatase Conservation Activities For Details; Integrated Report 35 © Kyowa Kirin Co., Ltd.
Slide 36: Governance
Appendix Governance 36 © Kyowa Kirin Co., Ltd.
Slide 37: Decent Governance System as a Listed Subsidiary
Decent Governance System as a Listed Subsidiary Decision-making process “Securing management independence” and -> Ensuring that independent outside directors are in the “Reasonable cooperation to maintain listing” majority -> An independent outside director elected as chairperson -> Clearly stat
Slide 38: Governance Highlights
Governance Highlights Basic Policy on Corporate A Transparent Governance Structure That Leverages the Strengths of Governance Outside Directors and Outside Audit & Supervisory Board Members Based on our philosophy that states that “The Kyowa Kirin Group companies strive to contribute to the health a
Slide 39: Governance Highlights: From the 2024 Integrated Report
Governance Highlights: From the 2024 Integrated Report Board Members with a Wide Array of Skills The Board of Directors comprises diverse individuals with various skills (knowledge, experience, etc.). This is to enable the Board of Directors to fulfill its decision- making and management oversight f
Slide 40: Governance Highlights: From the 2024 Integrated Report
Governance Highlights: From the 2024 Integrated Report Evaluation of the Board of Directors’ Effectiveness To identify gaps between expected roles and responsibilities of the Board of Directors set forth in the “Kyowa Kirin Corporate Governance Policy” and the actual state of the Board of Directors
Slide 41: © Kyowa Kirin Co., Ltd.
@yowa KIRIN 41 © Kyowa Kirin Co., Ltd.
Slide 42: @yOWa KIRIN
@yOWa KIRIN